Effect of somatostatin on abnormal growth hormone and prolactin secretion in patients with the carcinoid syndrome

A. Gomez-Pan, M. F. Scanlon, M. O. Thorner, L. H. Rees, Andrew V Schally, R. Hall, G. M. Besser

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Growth hormone (GH) secretion has been studied in two patients with the carcinoid syndrome during glucose loading and growth hormone-release inhibiting hormone (GHRIH), somatostatin) infusion. Both patients had elevated fasting GH levels which were not suppressed by glucose; GH levels fell rapidly during GHRIH infusion. One patient also had hyperprolactinaemia with galactorrhoea and the prolactin (PRL) levels were unaltered by GHRIH. The association between carcinoid tumours and abnormalities of GH and PRL secretion is discussed.

Original languageEnglish
Pages (from-to)575-581
Number of pages7
JournalClinical Endocrinology
Volume10
Issue number6
StatePublished - Dec 1 1979
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology

Cite this

Gomez-Pan, A., Scanlon, M. F., Thorner, M. O., Rees, L. H., Schally, A. V., Hall, R., & Besser, G. M. (1979). Effect of somatostatin on abnormal growth hormone and prolactin secretion in patients with the carcinoid syndrome. Clinical Endocrinology, 10(6), 575-581.